Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CELU Celularity	$3.61 -1.1%	$2.63	$1.00 ▼ $5.22	$86.46M	0.79	170,139 shs	141,927 shs
IGMS IGM Biosciences	$1.27	$1.27	$0.92 ▼ $22.50	$76.57M	0.6	480,746 shs	N/A
PMVP PMV Pharmaceuticals	$1.47 -0.7%	$1.30	$0.81 ▼ $1.82	$77.90M	1.52	206,418 shs	234,988 shs
QTTB Q32 Bio	$1.88 +1.4%	$1.88	$1.35 ▼ $53.79	$22.88M	N/A	642,062 shs	52,000 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CELU Celularity	+1.11%	+2.53%	+15.87%	+46.59%	+17.36%
IGMS IGM Biosciences	0.00%	0.00%	-0.78%	+5.83%	-87.22%
PMVP PMV Pharmaceuticals	-5.73%	-2.63%	+10.45%	+64.44%	-8.07%
QTTB Q32 Bio	+2.21%	+2.21%	-15.14%	+12.12%	-95.28%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CELU Celularity	0.7359 of 5 stars	2.0	1.0	0.0	1.9	1.7	0.0
IGMS IGM Biosciences	4.4973 of 5 stars	3.0	3.0	4.6	3.0	3.3	1.3
PMVP PMV Pharmaceuticals	2.3232 of 5 stars	3.5	3.0	0.0	0.0	2.5	0.6
QTTB Q32 Bio	2.5917 of 5 stars	3.1	4.0	0.0	1.9	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CELU Celularity	0.00	N/A	$6.00	66.20% Upside
IGMS IGM Biosciences	1.90	Reduce	$5.50	333.07% Upside
PMVP PMV Pharmaceuticals	3.00	Buy	$5.50	274.15% Upside
QTTB Q32 Bio	2.25	Hold	$12.17	548.89% Upside

Current Analyst Ratings Breakdown

Latest QTTB, PMVP, CELU, and IGMS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
8/18/2025	CELU Celularity	WBB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Moderate Buy	$6.00

(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CELU Celularity	$54.22M	1.59	N/A	N/A	$0.37 per share	9.76
IGMS IGM Biosciences	$145.05M	0.53	N/A	N/A	$1.67 per share	0.76
PMVP PMV Pharmaceuticals	N/A	N/A	N/A	N/A	$2.65 per share	N/A
QTTB Q32 Bio	$1.16M	19.72	N/A	N/A	($1.00) per share	-1.88

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CELU Celularity	-$57.89M	-$2.65	N/A	∞	N/A	-106.77%	-271.88%	-42.82%	N/A
IGMS IGM Biosciences	-$195.79M	-$0.90	N/A	N/A	N/A	-36.81%	-93.35%	-24.15%	N/A
PMVP PMV Pharmaceuticals	-$58.71M	-$1.57	N/A	N/A	N/A	N/A	-47.94%	-43.82%	11/6/2025 (Estimated)
QTTB Q32 Bio	-$47.73M	-$4.30	N/A	N/A	N/A	N/A	-2,709.70%	-61.16%	11/6/2025 (Estimated)

Latest QTTB, PMVP, CELU, and IGMS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	PMVP PMV Pharmaceuticals	-$0.39	-$0.41	-$0.02	-$0.41	N/A	N/A
8/6/2025	Q2 2025	QTTB Q32 Bio	-$1.14	-$0.78	+$0.36	-$0.78	N/A	N/A
7/31/2025	Q2 2025	IGMS IGM Biosciences	-$0.30	$1.58	+$1.88	$1.58	$3.20 million	$143.62 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CELU Celularity	N/A	N/A	N/A	N/A	N/A
IGMS IGM Biosciences	N/A	N/A	N/A	N/A	N/A
PMVP PMV Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
QTTB Q32 Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CELU Celularity	4.07	0.38	0.28
IGMS IGM Biosciences	N/A	17.66	17.66
PMVP PMV Pharmaceuticals	N/A	12.52	12.52
QTTB Q32 Bio	1.68	5.06	5.06

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CELU Celularity	19.02%
IGMS IGM Biosciences	42.79%
PMVP PMV Pharmaceuticals	90.20%
QTTB Q32 Bio	31.32%

Insider Ownership

Company	Insider Ownership
CELU Celularity	22.10%
IGMS IGM Biosciences	57.00%
PMVP PMV Pharmaceuticals	7.57%
QTTB Q32 Bio	40.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CELU Celularity	220	23.95 million	18.66 million	Optionable
IGMS IGM Biosciences	190	60.29 million	25.93 million	Optionable
PMVP PMV Pharmaceuticals	50	52.99 million	48.98 million	Optionable
QTTB Q32 Bio	39	12.20 million	7.32 million	N/A

QTTB, PMVP, CELU, and IGMS Headlines

Recent News About These Companies

Q32 Bio Inc. (NASDAQ:QTTB) Sees Significant Decline in Short Interest

August 21 at 2:26 AM | americanbankingnews.com

Q32 Bio Inc. (NASDAQ:QTTB) Receives Average Rating of "Hold" from Analysts

August 17, 2025 | americanbankingnews.com

Q32 Bio Inc. Advances Alopecia Areata Treatment with Phase 2a Trial of Bempikibart

August 15, 2025 | tipranks.com

Q32 Bio (QTTB) Projected to Post Earnings on Thursday

August 12, 2025 | americanbankingnews.com

Q32 Bio (QTTB) Q2 Loss Drops 45%

August 6, 2025 | fool.com

Q32 Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 6, 2025 | prnewswire.com

Q32 Bio Appoints Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer

June 25, 2025 | prnewswire.com

Q32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 8, 2025 | prnewswire.com

Q32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata

April 30, 2025 | prnewswire.com

Leerink Partners Sticks to Its Hold Rating for Q32 Bio (QTTB)

April 18, 2025 | markets.businessinsider.com

Q32 Bio Doses First Patients in Both Part A Open-Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia Areata

April 16, 2025 | prnewswire.com

All You Need to Know About Q32 Bio (QTTB) Rating Upgrade to Buy

April 8, 2025 | zacks.com

Analysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF) and Q32 Bio (QTTB)

March 12, 2025 | markets.businessinsider.com

Q32 Bio price target lowered to $15 from $16 at Wells Fargo

March 12, 2025 | markets.businessinsider.com

Q32 Bio Reports Promising Trial Results and Financials

March 11, 2025 | tipranks.com

Q32 Bio: Q4 Earnings Snapshot

March 11, 2025 | sfgate.com

Q32 Bio Reports Fourth Quarter 2024 Financial Results and Provides Corporate Update

March 11, 2025 | prnewswire.com

Q32 Bio presents results from SIGNAL-AA Part 2a trial of bempikibart

March 10, 2025 | markets.businessinsider.com

Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata at the 2025 American Academy of Dermatology Meeting

March 8, 2025 | prnewswire.com

Q32 Bio Announces Late-Breaking Presentation of Results from SIGNAL-AA Part A Clinical Trial of Bempikibart in Alopecia Areata at the 2025 American Academy of Dermatology Annual Meeting

February 28, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

QTTB, PMVP, CELU, and IGMS Company Descriptions

Celularity NASDAQ:CELU

$3.61 -0.04 (-1.10%)

Closing price 04:00 PM Eastern

Extended Trading

$3.57 -0.04 (-1.11%)

As of 05:12 PM Eastern

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.

IGM Biosciences NASDAQ:IGMS

$1.27 0.00 (0.00%)

As of 08/14/2025

IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.

PMV Pharmaceuticals NASDAQ:PMVP

$1.47 -0.01 (-0.68%)

Closing price 04:00 PM Eastern

Extended Trading

$1.50 +0.03 (+2.04%)

As of 05:05 PM Eastern

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.

Q32 Bio NASDAQ:QTTB

$1.88 +0.03 (+1.35%)

Closing price 04:00 PM Eastern

Extended Trading

$1.86 -0.01 (-0.80%)

As of 04:44 PM Eastern

Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time